Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ABEO 
Abeona Therapeutics Inc (ABEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/27/2025: ABEO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -57.46% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 215.98M USD | Price to earnings Ratio - | 1Y Target Price 16.75 |
Price to earnings Ratio - | 1Y Target Price 16.75 | ||
Volume (30-day avg) 254735 | Beta 1.78 | 52 Weeks Range 3.05 - 8.45 | Updated Date 04/2/2025 |
52 Weeks Range 3.05 - 8.45 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-17 | When Before Market | Estimate -0.3433 | Actual -0.3159 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.41% | Return on Equity (TTM) -216.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 141303401 | Price to Sales(TTM) 37.76 |
Enterprise Value 141303401 | Price to Sales(TTM) 37.76 | ||
Enterprise Value to Revenue 53.29 | Enterprise Value to EBITDA -0.58 | Shares Outstanding 48533800 | Shares Floating 34175074 |
Shares Outstanding 48533800 | Shares Floating 34175074 | ||
Percent Insiders 4.88 | Percent Institutions 68.52 |
Analyst Ratings
Rating 4.75 | Target Price 15.9 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Abeona Therapeutics Inc
Company Overview
History and Background
Abeona Therapeutics Inc. is a biopharmaceutical company focused on developing gene and cell therapies for serious diseases. Founded in 2002, it has focused on rare diseases with unmet needs. The company has undergone strategic shifts, including focusing on adeno-associated virus (AAV)-based gene therapies.
Core Business Areas
- Gene and Cell Therapy Development: Abeona develops gene and cell therapies for rare and life-threatening genetic diseases.
Leadership and Structure
Jou00e3o B. Siffert, M.D., is the current CEO. The organizational structure includes departments for research & development, clinical operations, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- EB-101 (recombinant gene-corrected cell therapy): EB-101 is Abeona's lead product candidate for recessive dystrophic epidermolysis bullosa (RDEB). Phase 3 data has been promising. Competitors include Castle Creek Biosciences and Krystal Biotech (KRYS), although KRYS has a different mechanism of action.
Market Dynamics
Industry Overview
The gene and cell therapy industry is rapidly growing, driven by advancements in technology and increasing regulatory support. It is also capital intensive and has a high rate of failure.
Positioning
Abeona is positioned as a developer of gene and cell therapies for rare diseases. Its competitive advantage lies in its proprietary AAV-based gene therapy platform and focus on unmet medical needs.
Total Addressable Market (TAM)
The TAM for RDEB is significant, estimated in the hundreds of millions to billions of dollars. Abeona's positioning depends on EB-101's market approval and successful commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary AAV-based gene therapy platform
- Focus on rare diseases with unmet needs
- Promising Phase 3 data for EB-101
- Experienced leadership team
Weaknesses
- Limited financial resources
- History of volatile stock performance
- Dependency on successful clinical trials
- Risk of regulatory setbacks
Opportunities
- Potential FDA approval for EB-101
- Expansion of pipeline into other rare diseases
- Strategic partnerships with larger pharmaceutical companies
- Increased investor interest in gene therapy
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from other gene therapy companies
- Difficulty in manufacturing gene therapies at scale
- Adverse events in trials
Competitors and Market Share
Key Competitors
- KRYS
- VRTX
- BLUE
Competitive Landscape
Abeona faces stiff competition from larger, more established gene and cell therapy companies. Abeonau2019s advantage lies in its focus on specific rare diseases and potential first-mover advantage in those indications, whereas the others have various indications.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's pre-commercial stage. However, significant milestone includes positive phase 3 results.
Future Projections: Future growth is highly dependent on the regulatory review and approval of EB-101. Analyst projections are contingent on these events.
Recent Initiatives: Recent initiatives include the completion of Phase 3 trials for EB-101, preparation for potential commercialization, and efforts to strengthen the company's financial position.
Summary
Abeona Therapeutics is a high-risk, high-reward biopharmaceutical company focused on gene and cell therapies for rare diseases. Positive Phase 3 data for EB-101 represents a significant milestone and potential catalyst for growth. However, the company's financial situation remains precarious and dependent on securing additional funding. Regulatory hurdles and competition pose ongoing challenges.
Similar Companies
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRIS
Curis Inc
CRIS
Curis Inc
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
KRYS
Krystal Biotech Inc
KRYS
Krystal Biotech Inc
NTLA
Intellia Therapeutics Inc
NTLA
Intellia Therapeutics Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This information is for informational purposes only and should not be considered financial advice. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abeona Therapeutics Inc
Exchange NASDAQ | Headquaters Cleveland, OH, United States | ||
IPO Launch date 1980-09-19 | President, CEO & Director Dr. Vishwas Seshadri M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | |
Full time employees 136 | |||
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.